413 related articles for article (PubMed ID: 32749910)
1. Switching to ocrelizumab in RRMS patients at risk of PML previously treated with extended interval dosing of natalizumab.
Mancinelli CR; Scarpazza C; Cordioli C; De Rossi N; Rasia S; Turrini MV; Capra R
Mult Scler; 2021 Apr; 27(5):790-794. PubMed ID: 32749910
[TBL] [Abstract][Full Text] [Related]
2. Switch to ocrelizumab in MS patients treated with natalizumab in extended interval dosing at high risk of PML: A 96-week follow-up pilot study.
Santiago-Setien P; Barquín-Rego C; Hernández-Martínez P; Ezquerra-Marigomez M; Torres-Barquin M; Menéndez-Garcia C; Uriarte F; Jiménez-López Y; Misiego M; Sánchez de la Torre JR; Setien S; Delgado-Alvarado M; Riancho J
Front Immunol; 2023; 14():1086028. PubMed ID: 36817456
[TBL] [Abstract][Full Text] [Related]
3. Evaluating the efficacy and safety of transitioning patients with multiple sclerosis from natalizumab to ocrelizumab (OCTAVE).
Smoot K; Marginean H; Gervasi-Follmar T; Chen C; Repovic P; Cohan S
Mult Scler; 2023 Jul; 29(8):956-966. PubMed ID: 37317841
[TBL] [Abstract][Full Text] [Related]
4. Mild progressive multifocal leukoencephalopathy after switching from natalizumab to ocrelizumab.
Toorop AA; van Lierop ZYG; Strijbis EEM; Teunissen CE; Petzold A; Wattjes MP; Barkhof F; de Jong BA; van Kempen ZLE; Killestein J
Neurol Neuroimmunol Neuroinflamm; 2021 Jan; 8(1):. PubMed ID: 33051344
[TBL] [Abstract][Full Text] [Related]
5. Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study.
Zanghì A; Gallo A; Avolio C; Capuano R; Lucchini M; Petracca M; Bonavita S; Lanzillo R; Ferraro D; Curti E; Buccafusca M; Callari G; Barone S; Pontillo G; Abbadessa G; Di Francescantonio V; Signoriello E; Lus G; Sola P; Granella F; Valentino P; Mirabella M; Patti F; D'Amico E
Neurotherapeutics; 2021 Apr; 18(2):1166-1174. PubMed ID: 33844155
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of extended versus standard interval dosing of natalizumab in multiple sclerosis patients: a systematic review and meta-analysis.
Rabea EM; Belal MM; Hafez AH; Elbanna AH; Khalifa MA; Nourelden AZ; Mahmoud NH; Zaazouee MS
Acta Neurol Belg; 2024 Apr; 124(2):407-417. PubMed ID: 38457005
[TBL] [Abstract][Full Text] [Related]
7. Progressive multifocal leukoencephalopathy in a patient with relapsing multiple sclerosis treated with ocrelizumab: A case report.
Puig-Casadevall M; Álvarez-Bravo G; Varela AQ; Robles-Cedeño R; Sànchez Cirera L; Miguela A; Laguillo G; Montalban X; Hauser SL; Ramió-Torrentà L
Eur J Neurol; 2023 Oct; 30(10):3357-3361. PubMed ID: 37485841
[TBL] [Abstract][Full Text] [Related]
8. No difference in radiologic outcomes for natalizumab patients treated with extended interval dosing compared with standard interval dosing: Real-world evidence from MS PATHS.
Ryerson LZ; Naismith RT; Krupp LB; Charvet LE; Liao S; Fisher E; de Moor C; Williams JR; Campbell N
Mult Scler Relat Disord; 2022 Feb; 58():103480. PubMed ID: 35051898
[TBL] [Abstract][Full Text] [Related]
9. Ocrelizumab versus fingolimod after natalizumab cessation in multiple sclerosis: an observational study.
Bigaut K; Kremer L; Fabacher T; Ahle G; Goudot M; Fleury M; Gaultier C; Courtois S; Collongues N; de Seze J
J Neurol; 2022 Jun; 269(6):3295-3300. PubMed ID: 34982200
[TBL] [Abstract][Full Text] [Related]
10. Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial.
Foley JF; Defer G; Ryerson LZ; Cohen JA; Arnold DL; Butzkueven H; Cutter G; Giovannoni G; Killestein J; Wiendl H; Smirnakis K; Xiao S; Kong G; Kuhelj R; Campbell N;
Lancet Neurol; 2022 Jul; 21(7):608-619. PubMed ID: 35483387
[TBL] [Abstract][Full Text] [Related]
11. Natalizumab in relapsing-remitting multiple sclerosis.
Outteryck O
Expert Rev Neurother; 2016 May; 16(5):471-81. PubMed ID: 27008031
[TBL] [Abstract][Full Text] [Related]
12. Natalizumab-associated progressive multifocal leukoencephalopathy is not preceded by elevated drug concentrations.
van Kempen ZL; Leurs CE; Vennegoor A; Wattjes MP; Rispens T; Uitdehaag BM; Killestein J
Mult Scler; 2017 Jun; 23(7):995-999. PubMed ID: 28112019
[TBL] [Abstract][Full Text] [Related]
13. Progressive multifocal leukoencephalopathy with natalizumab extended or standard interval dosing in the United States and the rest of the world.
Dsilva L; McCarthy K; Lyons J; Cabigas B; Campbell N; Kong G; Adams B; Kuhelj R; Singhal P; Smirnakis K
Expert Opin Drug Saf; 2023; 22(10):995-1002. PubMed ID: 37272350
[TBL] [Abstract][Full Text] [Related]
14. John Cunningham Virus Status, Seroconversion Rate, and the Risk of Progressive Multifocal Leukoencephalopathy in Polish John Cunningham Virus-Seronegative Patients with Relapsing-Remitting Multiple Sclerosis.
Kapica-Topczewska K; Collin F; Tarasiuk J; Czarnowska A; Chorąży M; Mirończuk A; Kochanowicz J; Kułakowska A
Eur Neurol; 2020; 83(5):487-492. PubMed ID: 33027785
[TBL] [Abstract][Full Text] [Related]
15. Switching from natalizumab to an anti-CD20 monoclonal antibody in relapsing remitting multiple sclerosis: A systematic review.
Brown JD; Muston BT; Massey J
Mult Scler Relat Disord; 2024 Jun; 86():105605. PubMed ID: 38640586
[TBL] [Abstract][Full Text] [Related]
16. Clinical and economic evaluations of natalizumab, rituximab, and ocrelizumab for the management of relapsing-remitting multiple sclerosis in Saudi Arabia.
Alharbi MA; Aldosari F; Althobaiti AH; Abdullah FM; Aljarallah S; Alkhawajah NM; Alanazi M; AlRuthia Y
BMC Health Serv Res; 2023 May; 23(1):552. PubMed ID: 37237257
[TBL] [Abstract][Full Text] [Related]
17. The comparative effectiveness of fingolimod, natalizumab, and ocrelizumab in relapsing-remitting multiple sclerosis.
Boz C; Ozakbas S; Terzi M; Karabudak R; Sevim S; Turkoglu R; Soysal A; Balcı BP; Efendi H; Turan ÖF; Yüceyar N; Yetkin MF; Karahan SZ; Demirkıran M; Guler S; Agan K; Kıylıoğlu N; Baba C; Tuncer A; Köseoğlu M
Neurol Sci; 2023 Jun; 44(6):2121-2129. PubMed ID: 36689010
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of natalizumab extended interval dosing.
Yamout BI; Sahraian MA; Ayoubi NE; Tamim H; Nicolas J; Khoury SJ; Zeineddine MM
Mult Scler Relat Disord; 2018 Aug; 24():113-116. PubMed ID: 29982107
[TBL] [Abstract][Full Text] [Related]
19. Reduced expression of L-selectin in T-cells correlates with relative lymphocyte increase in patients with RRMS treated with natalizumab - functional implication towards PML risk.
Boziki MK; Karapanayotides T; Papadopoulos G; Lagoudaki R; Melo P; Bakirtzis C; Nikolaidis I; Gounari E; Tsavdaridou V; Skoura L; Afrantou T; Tatsi T; Grigoriadou E; Polyzoidou E; Mandoras N; Giantzi V; Kalogera-Fountzila A; Ioannidis P; Parissis D; Pelidou SH; Zoidou S; Grigoriadis N
Neurol Res; 2020 Mar; 42(3):209-221. PubMed ID: 32048570
[No Abstract] [Full Text] [Related]
20. Assessing understanding of individual risk and symptoms of progressive multifocal leukoencephalopathy in patients prescribed natalizumab for multiple sclerosis.
Rath L; Vijiaratnam N; Skibina O
Intern Med J; 2017 Feb; 47(2):194-199. PubMed ID: 27862809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
